High diagnostic power of urinary-exosomal AMACR, ERG and PCA3 for patients with suspected prostate cancer

MLA

K. Erdmann, et al. “High Diagnostic Power of Urinary-Exosomal AMACR, ERG and PCA3 for Patients with Suspected Prostate Cancer.” European Urology Open Science, vol. 44, Oct. 2022, p. S168. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........0174461c050a367caa9b0a50630a634a&authtype=sso&custid=ns315887.

APA

K. Erdmann, A. Borkowetz, A. Lohse-Fischer, C. Thomas, & S. Fuessel. (2022). High diagnostic power of urinary-exosomal AMACR, ERG and PCA3 for patients with suspected prostate cancer. European Urology Open Science, 44, S168.

Chicago

K. Erdmann, A. Borkowetz, A. Lohse-Fischer, C. Thomas, and S. Fuessel. 2022. “High Diagnostic Power of Urinary-Exosomal AMACR, ERG and PCA3 for Patients with Suspected Prostate Cancer.” European Urology Open Science 44 (October): S168. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........0174461c050a367caa9b0a50630a634a&authtype=sso&custid=ns315887.